Gyre Therapeutics, Inc. · Brief

Next report

6 days

Nov 6 · after closeest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

0 of 6≥ implied

Feb 18 '25—▲+6.01%—

Mar 17 '25—▼−30.21%—

May 9 '25±38.0%▲+0.53%×0.01

Aug 11 '25±51.5%▲+6.93%×0.13

Q3 FY25±71.0%▼−1.77%×0.02

Q1 FY26±56.7%▼−6.30%×0.11

May 7 '26±42.3%▼−12.06%×0.29

Q2 FY26±65.8%▲+4.22%×0.06

quarterimplied−75%0+75%realized×

Q2 FY26±65.8%▲+4.22%×0.06

May '26±42.3%▼−12.06%×0.29

Q1 FY26±56.7%▼−6.30%×0.11

Q3 FY25±71.0%▼−1.77%×0.02

Aug '25±51.5%▲+6.93%×0.13

May '25±38.0%▲+0.53%×0.01

2 older reports

Mar '25—▼−30.21%—

Feb '25—▲+6.01%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 6 report · est.

Bull2 of 3

58managers reporting a position in the latest quarter13F · Jun 30 '26

3tracked funds holding GYREN-PORT · Aug 31 '26

Bear2

100.00%revenue from the largest disclosed distributor customerSEC filings

4 of 20largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

AI captions · Oct 5 '26once per report · top 2 per case

GYRE report session

No linked exposure.

Oct 23impliedImplied move: ±56.9% into Nov 6 earnings (Oct 23 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.